We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novartis has agreed to sell products in three European countries to gain final European Union (EU) approval for its planned merger of German generic drugmaker Hexal AG and Hexal's U.S. sister company Eon Labs, the European Commission (EC) announced May 27.
The FTC is weighing the merits of conducting a study on the competitive effects of authorized generics, but it is looking for input from drugmakers before deciding how to proceed on the matter, an agency official told a recent industry conference.
A bipartisan group of state legislators has urged the FTC to stop defending the pharmaceutical benefit manager (PBM) industry and to crack down on “deceptive and fraudulent practices” utilized by PBMs.
Johnson & Johnson (J&J) received approval from the Federal Trade Commission (FTC) to acquire Raleigh, N.C.-based Closure Medical, a maker of wound-healing products.
The FTC has asked a federal appeals court to reconsider a March ruling in which a three-judge panel dismissed the agency’s charges that drugmaker Schering-Plough engaged in anticompetitive business practices by making “reverse payments” to two generic firms.
The FTC has asked a federal appeals court to reconsider a March ruling in which a three-judge panel dismissed the agency’s charges that drugmaker Schering-Plough engaged in anticompetitive business practices by making “reverse payments” to two generic firms.
In a victory for pharmaceutical firms, a federal appeals court has overruled an FTC mandate that attempted to prevent drug patent holders from paying generic manufacturers to keep less-expensive versions of branded products off the market.
A federal appeals court has overruled an FTC mandate that attempted to prevent pharmaceutical firms from paying generic manufacturers to keep less-expensive versions of branded products off the market.
In a victory for pharmaceutical firms, a federal appeals court has overruled an FTC mandate that attempted to prevent drug patent holders from paying generic manufacturers to keep less-expensive versions of branded products off the market.
The FTC has again thrown its weight behind Teva Pharmaceutical’s patent challenge to Pfizer’s antidepressant Zoloft, stating in a recently filed court brief that a federal appeals court erred in its recent decision on the hotly contested declaratory judgment issue.